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The basal extracellular concentration of dopamine in the nucleus accumbens was quantified using the 'no net flux' microdialysis method, in rats 
undergoing withdrawal from o-amphetamine. Rats were initially pretreated with saline, or an escalating dose amphetamine regimen known to 
produce a robust withdrawal syndrome, and extracellular dopamine was quantified 3 or 28 days after the last pretreatment injection. There was no 
effect of amphetamine pretreatment on the basal extracellular concentration of dopamine in the nucleus accumbens, or on the 'in vivo recovery" of 
dopamine, estimated by 'no net flux' microdialysis. It is suggested that amphetamine withdrawal is not necessarily accompanied by changes in the 
basal extracellular concentration of dopamine in the nucleus accumbens. 
Following the discontinuation of chronic ampheta- 
mine use, humans develop withdrawal symptoms similar 
to those associated with endogenous depression, includ- 
ing excessive sleep, lethargy, fatigue, and dysphoria [1, 3, 
14]. Rats also show an amphetamine withdrawal syn- 
drome, and the symptoms include behavioral hypoactiv- 
ity [13] and a decrease in the efficacy of intracranial self- 
stimulation reward (ICSS) [2]. For example, for at least 
7 days following the discontinuation of an escalating 
dose amphetamine regimen, rats exhibit both a decrease 
in spontaneous nocturnal locomotion [7, 8], and an in- 
crease in the threshold required to maintain ICSS [5]. By 
28 days of withdrawal, both spontaneous motor activity 
and ICSS thresholds return to control levels [5, 7]. 
There is considerable interest in the nature of the neu- 
roadaptations underlying the symptoms of drug with- 
drawal, and recent research has focused on the role of 
mesotelencephalic dopamine systems. Indeed, it is re- 
ported that withdrawal from not only amphetamine, but 
from a number of addictive drugs, including morphine, 
alcohol and cocaine, is associated with a decrease in the 
basal extracellular concentration of dopamine in the ven- 
tral striatum [10, 11]. The purpose of this study was to 
reexamine the hypothesis that amphetamine withdrawal 
is associated with a decrease in dopamine neurotransmis- 
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sion in the ventral striatum, using the 'no net flux' micro- 
dialysis method [4]. 
Drug pretreatment. Male Holtzman rats, initially 
weighing 300-500 g, were housed individually in wire 
hanging cages on a 14:10 light/dark cycle (lights on at 
07.00 h), with free access to food and water. Rats were 
pretreated with D-amphetamine sulfate (weight of the 
salt) using an escalating-dose regimen (1 to 10 mg/kg, 
i.p.), in which the drug was administered twice daily, 5 
days per week for 6 weeks, as described previously [7]. 
Control rats received 0.9% saline, and all injections were 
given in the home cage. 
Surgical and microdialysis procedures. After 4 to 5 
weeks of drug pretreatment, and on the first of 2 drug- 
free days, each rat was anesthetized with sodium pento- 
barbital and a single 22-gauge stainless steel guide can- 
nula was fixed stereotaxically on the dural surface above 
the nucleus accumbens. Pretreatment injections resumed 
2 days later. Either 2 or 27 days after the final injection, 
each animal was placed in a 30 × 50 cm plexiglass cham- 
ber, and a concentric dialysis probe (O.D. 250 pm,  2 mm 
effective length) was inserted into the nucleus accumbens 
via the guide cannula. The probe was perfused with a 
solution containing 145 mM NaC1, 2.7 mM KCI, 1.2 
mM CaC12, 1.0 mM MgCI~ and 0.2 mM ascorbic acid 
(pH 7.3) at 0.3 ~l/min. (See ref. 9 for details concerning 
the dialysis procedures.) The animals were then left un- 
disturbed overnight. The next morning (3 or 28 days 
after the last injection) the perfusion rate was increased 
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to 1.5 ~l/min and, after a minimum stabilization period 
of  1 h, at least four 30 rain samples of  dialysate were 
collected. These samples represent, therefore, a conven- 
tional dialysis experiment. The perfusion solution de- 
scribed above, which contained 0 nM of dopamine, was 
then changed to one containing (in addition to the salts) 
2.5, 5 or 10 nM of  dopamine in a pseudo-random order, 
as described by Parsons and Justice [6]. After a 90 rain 
equilibration period, three additional dialysate samples 
were collected. (Pilot work revealed that within 90 min 
the dialysate concentrations of  dopamine were stable; 
that is, successive samples varied by less than 10%.) This 
procedure was then repeated for each of  the two remain- 
ing concentrations of  dopamine. Thus, each animal was 
perfused first with a perfusion solution containing 0 nM 
of  dopamine,  followed by solutions containing 2.5, 5 and 
10 nM of  dopamine. Dopamine in dialysate was sepa- 
rated by H P L C  and analyzed using electrochemical de- 
tection, as described previously [9]. The perfusion solu- 
tions containing 0, 2.5, 5 and 10 nM of dopamine were 
used for the chromatographic  standards. 
All probes were tested for recovery of  dopamine in 
vitro prior to use, and there were no group differences in 
in vitro recovery, which averaged (+ S.E.M.) 
14.2 + 0.94% for dopamine. In addition, only animals 
whose probes were histologically verified to have at least 
75% of  the dialysis surface within the nucleus accumbens 
were retained in the experiment. 
Fig. 1 depicts the net flux of  dopamine across the dial- 
ysis membrane  for each of  the three groups, as a function 
of the concentration of  dopamine in the perfusion solu- 
tion. The analysis illustrated in Figure 1 provides two 
important  values. The first is the point of  'no net flux'; 
that is, the concentration of  dopamine in the perfusion 
solution at which dopamine diffusion into the probe 
equals that out of  the probe. This value provides an esti- 
mate of  the true extracellutar concentration of  dopamine 
[6]. It  is evident in Figure 1 that there was no change in 
the point of  'no net flux' of  dopamine in association with 
amphetamine withdrawal. The mean (_ S.E.M.) ex- 
tracellular concentration of  dopamine for each group, 
derived from linear regression analyses, was: saline pre- 
treated, 4.726 nM (+ 0.676); 3-day amphetamine with- 
drawal, 5.109 nM (+ 0.504); 28-day amphetamine with- 
drawal, 4.716 nM (+ 0.107). 
The second important  value derived f rom Fig. 1 is the 
slope of  the regression line, which represents 'in vivo re- 
covery'  [6]. Again, there were no significant group differ- 
ences. The mean 'in vivo recovery'  value for each group 
was: saline pretreated, 23.7 _+ 3.6%; 3-day amphetamine 
withdrawal, 26.1 +4.1%; 28-day amphetamine with- 
drawal, 24.2 + 2.2%. As reported previously [6], recov- 
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Fig. 1. Doparnine net flux (the concentration of dopamine into the 
probe minus the concentration of dopamine out of the probe) across 
the dialysis membrane in the nucleus accumbens, plotted as a function 
of the concentration of dopamine in the perfusion solution. Symbols 
represent group means + S.E.M. Negative values on the y-axis indicate 
net dopamine diffusion from the brain into the probe, and positive 
values indicate net diffusion into the brain from the probe. The point of 
zero flux ('no net flux') for each animal was extrapolated from a linear 
regression line, and this point represents the concentration of dopamine 
at which diffusion into the probe equals that out of the probe. This 
value presumably is equal to the 'true' extracellular concentration of 
dopamine [6]. There was no significant effect of amphetamine with- 
drawal on the point of no net flux (Fz.~2 = 0.24. P = 0.79). The slope of 
the regression line indicates the rate of 'in vivo recovery', or efficiency, 
of the probe [6]. There was no significant effect of amphetamine with- 
drawal on this measure (Fa.t2 = 0.127. P = 0.88}. The r 2 values shown 
on the figure indicate that for all 3 groups over 98% of the variance in 
the data can be attributed to a linear relationship between the net flux 
of dopamine across the probe membrane, and the concentration of 
dopamine in the perfusate. The open circles represent values for saline- 
pretreated rats (n = 4), the closed triangles values for amphetamine- 
pretreated rats withdrawn for 3 days (n = 6), and the open squares 
values for amphetamine-pretreated rats withdrawn for 28 days (n = 5). 
Note  that the dopamine net flux values for the 0 nM 
dopamine perfusion solution represent a conventional 
dialysis experiment. There was also no effect of  ampheta-  
mine withdrawal when these values were analyzed sepa- 
rately (F2,12 = 0.869, P = 0.44). In addition, there was no 
significant effect o f  amphetamine withdrawal, or  the ad- 
dition of  dopamine to the perfusion solution, on the con- 
centration of  DOPAC in dialysate (data not shown). 
In the present study rats were pretreated with d-am- 
phetamine using an aggressive dosing regimen, in which 
animals received two injections per day, with dose gradu- 
ally escalating from 1 to 10 mg/kg over 6 weeks. The 
discontinuation of  this amphetamine pretreatment regi- 
men is associated with a marked withdrawal syndrome 
147 
that lasts for at least 7 days, and consists in part of 'be- 
havioral depression' and changes in motivated behavior 
[5, 7]. In the present study, however, amphetamine with- 
drawal was not associated with any change in the ex- 
tracellular concentration of dopamine in the nucleus ac- 
cumbens, or in the 'in vivo recovery' of dopamine, as 
determined by 'no net flux' microdialysis. 
In contrast, using conventional dialysis techniques, 
Rossetti et al. [10] found that extracellular dopamine is 
significantly decreased in the ventral striatum for up to 5 
days following the discontinuation of amphetamine pre- 
treatment. There are several differences between the 
present study and that by Rossetti and his colleagues [10] 
that could potentially account for the discrepancy. 
First, different microdialysis methods were used. As 
mentioned above, Rossetti et al. [10] used conventional 
dialysis methods, and the °no net flux' method was used 
here. This is not a plausible explanatiom however, be- 
cause a conventional dialysis experiment was incorpo- 
rated into the present experiment, and there was no effect 
of amphetamine withdrawal on dopamine when these 
data were analyzed separately. In addition, using con- 
ventional microdialysis methods, both Segal and 
Kuczenski [12] and Wolf et al. [15] report no change in 
the basal extracellular concentration of dopamine in the 
nucleus accumbens during the first 5 days of ampheta- 
mine withdrawal, consistent with the 'no net flux' data 
reported here. Furthermore, we have used conventional 
on-line dialysis methods to sample dopamine across the 
entire light/dark cycle in animals tested 3, 7 or 28 days 
following discontinuation of the escalating dose amphet- 
amine regimen used here (P. Paulson and T. Robinson. 
unpublished experimentsL and found no effect of am- 
phetamine withdrawal on basal dopamine concentra- 
tions in the nucleus accumbens. The discrepancy does 
not appear to be due, therefore, to differences between 
conventional and 'no net flux' dialysis methods. 
Second~ different amphetamine pretreatment regimens 
were used in the two experiments. One could postulate 
that the regimen used by Rossetti et al. [10] produced a 
more pronounced withdrawal syndrome than the regi- 
men used here~ but this seems unlikely. In the present 
study the dose of amphetamine was escalated from I to 
10 mg/kg over 6 weeks, for a total of 60 injections (cumu- 
lative dose = 356 mg/kg), and this regimen is known to 
produce a marked behavioral withdrawal syndrome last- 
ing for at least seven days [5, 7, 8]. In contrast, Rossetti 
et al. [10] gave a constant dose of only 1.5 mg/kg over 16 
days, for a total of 32 injections (cumulative dose = 48 
mg/kg). In addition, both Segal and Kuczenski [12] and 
Wolf et al. [15] used a relatively moderate pretreatment 
regimen, and as here, found no effect of amphetamine 
withdrawal on extracellular dopamine. 
Another difference in the pretreatment regimens is 
that Rossetti et al. [10] gave amphetamine every day for 
16 successive days, whereas in the present study amphet- 
amine was given in six weekly cycles of 5 successive drug 
days followed by 2 drug-free days. There were also 2 
drug-free days between two 5-day cycles of amphetamine 
pretreatment in the Wolf et al. [15] experiment. There- 
fore, in the experiment by Rossetti et al. [10], animals 
experienced withdrawal for the very first time when un- 
dergoing microdialysis. But in the present study animals 
experienced withdrawal five times prior to the microdi- 
alysis test session, and in the Wolf et al. [15] study once 
previously. It is interesting to speculate, therefore, that 
the extracellular concentration of dopamine may be af- 
fected differently by the first experience with withdrawal 
than it is by subsequent experiences with withdrawal. 
This hypothesis is not supported, however, by the Segal 
and Kuczenski [12] study, in which the dialysis test ses- 
sion took place during the first experience with with- 
drawal. In addition, the behavioral and psychological 
symptoms of withdrawal should not dissipate with re- 
peated withdrawal, but should be enhanced. Therefore, 
even if there were an effect of previous experience with 
withdrawal, the results reported here would suggest that 
a decrease in the extracellular concentration of dopamine 
in the nucleus accumbens is not necessarily associated 
with symptoms of amphetamine withdrawal. 
A third difference between the present study and Ros- 
setti et al. [10] is that different style microdialysis probes 
were used. Rossetti et al. [10] used horizontal transverse 
probes that sampled the ventral striatum, whereas in this 
study concentric probes were placed vertically into the 
nucleus accumbens. Segal and Kuczenski [12] and Wolf 
et al. [15] also used concentric-style probes, and Segal 
and Kuczenski [12] sampled the medial striatum in addi- 
tion to the nucleus accumbens. Nevertheless, the differ- 
ent probe designs necessarily result in sampling slightly 
different regions in the ventral striatum. Perhaps more 
important, however, use of a transverse probe requires a 
major surgical procedure, including surgical levels of an- 
esthesia, the day before a dialysis test session. In this 
study no surgery or anesthesia was required at the time 
of probe implantation, because the probes were simply 
lowered via a previously implanted guide cannula. It is 
possible, therefore, that there is an interaction between 
amphetamine withdrawal and the trauma associated 
with surgery, which affects basal extracellular dopamine 
concentrations measured the next day. 
In summary, we found that amphetamine withdrawal 
was not accompanied by changes in the basal extracellu- 
lar concentration of dopamine in the nucleus accumbens, 
or in the 'in vivo recovery' of dopamine, as determined 
by 'no net flux' microdialysis. Although there may be a 
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correlation between amphetamine withdrawal and the 
basal concentration of dopamine in ventral striatal dialy- 
sate under some experimental conditions, this study sug- 
gests it is not an obligatory relationship [12, 15, as well]. 
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